ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,563.14
-0.02%
US Tech 100
19,273.60
-0.16%
Dow Jones
40,416.95
0.00%
Brent Oil
80.645
-1.07%
Bitcoin
65,604.95
-2.95%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Caribou Biosciences Inc (CRBU) Quote

Caribou Biosciences Inc

Caribou Biosciences Inc (CRBU)

Amd Commo Exagr
2.41
0.09
( 3.88% )
Updated: 15:35:17
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
2.41
Bid
2.40
Ask
2.41
Volume
1,074,415
2.2206 Day's Range 2.44
1.50 52 Week Range 8.33
Market Cap
217.666M
Previous Close
2.32
Open
2.31
Last Trade
100
@
2.41
Last Trade Time
15:35:32
Financial Volume
$ 2,557,839
VWAP
2.3807
Average Volume (3m)
2,687,345
Shares Outstanding
90,317,771
Dividend Yield
-
PE Ratio
-2.12
Earnings Per Share (EPS)
-1.13
Revenue
34.48M
Net Profit
-102.07M

About Caribou Biosciences Inc

Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies.

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.cariboubio.com
Headquarters
Dover, Delaware, USA
Founded
1970
Caribou Biosciences Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker CRBU. The last closing price for Caribou Biosciences was $2.32. Over the last year, Caribou Biosciences shares have traded in a share price range of $ 1.50 to $ 8.33.

Caribou Biosciences currently has 90,317,771 shares outstanding. The market capitalization of Caribou Biosciences is $209.54 million. Caribou Biosciences has a price to earnings ratio (PE ratio) of -2.12.

CRBU Latest News

More News

Form 8-K - Current report

July 16 2024
Edgar (US Regulatory)

Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board

-- Dr. Laufer is an immunologist advancing the scientific understanding and treatment of autoimmune diseases -- BERKELEY, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences...

July 09 2024
GlobeNewswire Inc.

Form 8-K - Current report

June 14 2024
Edgar (US Regulatory)

Form 8-K - Current report

June 03 2024
Edgar (US Regulatory)

Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

-- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in...

June 02 2024
GlobeNewswire Inc.

Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences

BERKELEY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the...

May 30 2024
GlobeNewswire Inc.

Form 8-K - Current report

May 07 2024
Edgar (US Regulatory)

Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update

-- Advancing CB-010 ANTLER Phase 1 trial in 2L LBCL; initial dose expansion data to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting -- -- Expanding into...

May 07 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.2411.05990783412.172.7452.0837720322.60797395CS
40.5529.56989247311.862.7451.524126482.09449861CS
12-1.37-36.24338624343.783.931.526873452.43869049CS
26-3.07-56.02189781025.488.331.520811633.74771032CS
52-4.3-64.08345752616.718.331.518567974.50951533CS
156-15.24-86.345609065217.6532.6451.512311527.09169629CS
260-15.24-86.345609065217.6532.6451.512311527.09169629CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DCAPUnity Wealth Partners Dynamic Capital Appreciation & Options ETF
 20.10
(839.25%)
128.77k
RGCRegencell Bioscience Holdings Ltd
$ 18.66
(453.71%)
1.11M
SLRXSalarius Pharmaceuticals Inc
$ 2.66
(72.73%)
59.28M
ALPPAlpine 4 Holdings Inc
$ 0.8296
(72.29%)
2.32M
ADILAdial Pharmaceuticals Inc
$ 1.48
(39.62%)
158.31M
FLYEFly E Group Inc
$ 1.0302
(-83.85%)
23.02M
RNAZTransCode Therapeutics Inc
$ 0.2991
(-62.26%)
9.1M
JAGXJaguar Health Inc
$ 1.7201
(-59.72%)
14.66M
IVPInspire Veterinary Partners Inc
$ 4.74
(-48.70%)
1.41M
MIRAMIRA Pharmaceuticals Inc
$ 2.67
(-46.71%)
24.84M
SPWRSunPower Corporation
$ 0.9558
(33.53%)
178.53M
SLNASelina Hospitality PLC
$ 0.0264
(-28.65%)
158.33M
ADILAdial Pharmaceuticals Inc
$ 1.48
(39.62%)
158.31M
NVDANVIDIA Corporation
$ 122.845
(-0.56%)
141.07M
HOLOMicroCloud Hologram Inc
$ 0.5501
(17.95%)
113.04M

CRBU Discussion

View Posts
jondoeuk jondoeuk 2 days ago
Earlier this year development of the lead CAR-NK programme, CB-020, was stopped, and now they are out of CAR-NK altogether. They disclosed it in an SEC filing and outlined a 12% workforce reduction https://www.sec.gov/Archives/edgar/data/1619856/000161985624000054/crbu-20240716.htm

This should extend their cash runway by at least six months, into the second half of 2026.
👍️0
Monksdream Monksdream 2 days ago
CRBU under $3
👍️0
Monksdream Monksdream 3 weeks ago
CRBU new 52 week low
👍️0
Monksdream Monksdream 1 month ago
CRBU new 52 week low
👍️0
NY1972 NY1972 1 month ago
Without engaging macrophage long term, CART and other ACT will have persistence issue as regulatory lymphocytes and TAM recoup. AFMD has the best approach with ICE engaging a few B CBNK cells for start and engaging endogenous NK and M in the maintenance phase
👍️0
Diego Rivas Diego Rivas 2 months ago
Any good news in here comming?
👍️0
jondoeuk jondoeuk 2 months ago
Among patients with four or more matching HLA alleles, mPFS was 14.4 months, versus 2.8 months in patients with three or fewer matches. But this is based on a retrospective analysis, so they will need to prove the theory prospectively. It was better in LBCL, with mPFS not reached, versus 2.8 months. Also, some improvement in the now-selected dose, 80 million CAR-T cells.
👍️0
jondoeuk jondoeuk 2 months ago
The BCMA-targeted space is already crowded enough and off-target toxicities, including agranulocytosis* could be a problem for its anti-CLL-1 CAR.

* CLL-1 is also highly expressed on almost all granulocytes and monocytes and on parts of myeloid progenitors in the normal bone marrow and peripheral blood.
👍️0
Monksdream Monksdream 2 months ago
CRBU new 52 week low
👍️0
stocksrising stocksrising 2 months ago
Yep, not a positive trend hence sub $3’s…fortunately other trials for varied indications could save company…
👍️0
jondoeuk jondoeuk 2 months ago
It gets worse. The updated (CB-010) data shows that the ORR (including CR rate) has fallen, so has the mDOR, the six-month PFS is poor and the pivotal trial has been delayed until H2 2025 following a new HLA partial matching strategy. The latter completely alters (in a bad way) the commercial strategy for an allo CAR-T product. They now need thirteen different off-the-shelf batches to be able to cater to ~90% of patients based on an ideal HLA match.
👍️ 1
Monksdream Monksdream 2 months ago
CRBU new 52 week low
👍️0
Monksdream Monksdream 2 months ago
CRBU new 52 week low
👍️0
Monksdream Monksdream 3 months ago
CRBU under $5
👍️0
stocksrising stocksrising 4 months ago
It seemed like they were running on all positive cylinders, but must have blown a gasket at current Conference/ Fireside???
👍️0
Monksdream Monksdream 9 months ago
CRBU new 52 week low
👍️0
jondoeuk jondoeuk 1 year ago
Yes, with both drugs still in development. As for CRBU, they gave an update (plus public offering) https://finance.yahoo.com/news/caribou-biosciences-reports-positive-clinical-200100822.html https://investor.cariboubio.com/static-files/d818ed1a-aea2-41c1-84ea-bd05a4276cbb

Personally, there seem to be red flags, such as no expansion/persistence data. I know they give huge amounts of LD chemo, higher (I think) than anyone else, which could be generating responses, explaining why there is no dose response.
👍️0
trueblue trueblue 1 year ago
.
👍️0
trueblue trueblue 1 year ago
$23.00 price target! Now that is a good start!! Glad I loaded up! Jmo
👍️0
NY1972 NY1972 1 year ago
Didn't they buy TRIL? Just gambling with billions from US government.
👍️0
jondoeuk jondoeuk 1 year ago
PFE is very selective in who they fund https://finance.yahoo.com/news/caribou-biosciences-announces-25-million-120000433.html
👍️0
trueblue trueblue 1 year ago
Great day in my accounts again! Really liking my CRBU shares! Jmo holding for the long haul!!
👍️0
Monksdream Monksdream 1 year ago
CRBU now No 9 on the Barchart Top 10
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0
trueblue trueblue 1 year ago
Added to my existing shares today, I bought shares months ago. I like Crbu a crisper company! Looks like Pfizer does also! Jmo
👍️0
Stockexpertpro Stockexpertpro 1 year ago
CRBU Loss 108 Million Dollars Company only has preclinical and phase 1 in its pipeline company is Years away from having anything if ever did a stock offering at 5.33$ for 25 Million thats only 1 QTR Cash burn for this company Sell the News https://www.cariboubio.com/pipeline/
👍️0
TheFinalCD TheFinalCD 1 year ago
CRBU= JUST WOW

https://finviz.com/quote.ashx?t=CRBU&ty=c&ta=1&p=d
👍️0
Monksdream Monksdream 1 year ago
CRBU No 1 on the early Barchart Top 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0

Your Recent History

NASDAQ
CRBU
Caribou Biosciences
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved